Lineage Cell announces 36-month results from Phase 1/2a study of RG6501

Lineage Cell Therapeutics (LCTX) announced that 36-month results from patients enrolled in a Phase 1/2a clinical study of RG6501 in patients with geographic atrophy secondary to age-related macular degeneration, were presented at the Foundation Fighting Blindness’ Retinal Therapeutics Innovation Summit 2026. The presentation, “Retinal Pigment Epithelium Cell Therapy in Geographic Atrophy Secondary to Age-related Macular Degeneration: 3 Year Results from the Phase 1/2a Study,” was presented by Eyal Banin, M.D., Ph.D., Center for Retinal and Macular Degenerations, Department of Ophthalmology Hadassah-Hebrew University Medical Center and Faculty of Medicine, on behalf of Roche and Genentech, a member of the Roche (RHHBY). Key highlights: Gains in best corrected visual acuity of +9 letters at 36 months among patients with extensive coverage of OpRegen cell therapy to the geographic atrophy lesion site; OCT imaging indicated partial restoration of outer retinal structure, re-appearance of an RPE layer, and features associated with recovery of photoreceptors; Anatomical and functional improvements occur following a single administration of OpRegen cell therapy